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Abstract
The cytotoxic mechanism of the histone deacetylase
inhibitor (HDACI) Trichostatin A (TSA)was explored in a
neuroblastoma (NB) model. TSA induces cell death in
neuroblastic-type NB cells by increasing the acetyla-
tion of Ku70, a Bax-binding protein. Ku70 acetylation
causesBax release and activation, triggering cell death.
This response to TSA depends on the CREB-binding
protein (CBP) acetylating Ku70. TSA-induced cell death
response correlates with CBP expression. In stromal-
type NB cell lines with low levels of CBP and relative
resistance to TSA, increasing CBP expression disrupts
Bax–Ku70 binding and sensitizes them to TSA. Re-
ducing CBP expression in neuroblastic cell types
causes resistance. Cytotoxic response to TSA is Bax-
dependent. Interestingly, depleting NB cells of Ku70
also triggers Bax-dependent cell death, suggesting that
conditions that leave Bax unbound to Ku70 result in
cell death. We also show that CBP, Ku70, and Bax are
expressed in human NB tumors and that CBP expres-
sion varies across cell types comprising these tumors,
with the highest expression observed in neuroblastic
elements. Together, these results demonstrate that
CBP, Bax, and Ku70 contribute to a therapeutic re-
sponse to TSA against NB and identify the possibility
of using these proteins to predict clinical responsive-
ness to HDACI treatment.
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Introduction
Protein function can be regulated by posttranslational modi-
fications, including phosphorylation, sumoylation, ubiquiti-
nation, and acetylation. The acetylation status of proteins is
regulated by two groups of enzymes: histone acetyltrans-
ferases (HATs), including CREB-binding protein (CBP) and
p300, and histone deacetylases (HDACs). Despite the no-
menclature, both HATs and HDACs act on nonhistone pro-
teins as well as on histones [1], and protein acetylation is
involved in the regulation of nearly every major cellular pro-
cess. As such, activators and inhibitors of HATs and HDACs
are important to understanding molecular regulation and are
of increasing interest as therapeutic agents. For example, in-
hibitors of HDACs have been approved for clinical use as anti-
tumor agents [2]. Despite evidence supporting their efficacy in
several types of cancer, molecular mechanisms linking HDAC
inhibition to effects on cell survival and growth are not under-
stood. Consequently, the HDAC sensitivity or resistance of
tumors cannot be rationally predicted.
Because histones and transcription factors were the first
proteins to be identified as HDAC substrates, gene transcription
and chromatin remodeling were the initial foci of experiments
studying the antitumor mechanisms of histone deacetylase in-
hibitors (HDACIs) [3]. However, we have provided strong evi-
dence for a non–chromatin-based mechanism, involving Ku70
protein, that accounts for antitumor proapoptotic response in
neuroblastoma (NB) tumor cells [4]. In neuroblastic NB cell
lines (N-type) analogous to the predominant tumor cell type in
NB tumors, about 50% of Ku70 protein is localized in the cytosol
where it is bound to Bax, a multidomain proapoptotic member
of the Bcl-2 family of proteins [5]. Ku70 was originally charac-
terized as an autoantigen protein [6,7], which is essential for
the repair of nonhomologous DNA double-strand breaks as
part of the DNA-binding component of DNA-dependent pro-
tein kinase [8,9]. Distinct from this biochemical activity, Ku70
regulates tumor cell survival through its association with Bax
[10]. The carboxy-terminal region of Ku70, which binds Bax,
contains a domain that interacts with HATs (CBP and p300/
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CBP–associated factor) [10]. Specific residues in this domain
can be acetylated (lysine-539 and lysine-542), preventing or
disrupting Bax binding. Treating cells with Trichostatin A (TSA;
an inhibitor of class I/II HDACs) or nicotinamide (a class III
HDACI) increases the acetylation of these residues [10], dis-
rupts the Ku70–Bax complex, and sends Bax to the mito-
chondria to trigger apoptotic cell death. Thus, it appears that
the balance of acetylation on these key regulatory sites is, at
least partially, determined by HDACs [11]. Moreover, high
levels of Ku70 expression are observed in N-type cell lines.
Although this may be a factor that limits cellular sensitivity to
radiation and certain types of chemotherapy, the cellular
sensitivity of N-type cell lines to HDACIs appears instead to
be directly proportional to Ku70 expression.
In addition to neuroblastic cells, NB tumors contain a
second tumor-derived or tumor-associated cell population,
stromal-type (S-type) cells. Whereas N-type cell lines ex-
press N-myc protein and neuronal markers, represent a
larger fraction of total tumor cells in high-risk tumors, and
are tumorigenic in xenografts, S-type cell lines do not ex-
press N-myc, express stromal cell markers, are not tumori-
genic in mice, and are associated with less malignant tumor
behavior. We conducted experiments to determine if the
response of S-type NB tumor cell lines to TSA was similar
to that of N-type cell lines. Interestingly, S-type NB cells are
significantly less sensitive to this HDACI. This lack of re-
sponsiveness is seen both with overall cell survival and at the
mechanistic level of disruption of the Bax–Ku70 complex.
Comparing S-type cell lines with N-type cell lines showed
that CBP is differentially expressed (higher in N-type than
S-type) so as to potentially account for differential respon-
siveness. When CBP expression was increased in S-type
cell lines, TSA treatment results in cell death mediated by
Bax release that depends on acetylation-sensitive sites in
Ku70. When CBP expression in N-type cell lines was re-
duced, cells became relatively resistant to TSA treatment.
Reducing Bax expression in these cells, like decreasing
CBP, similarly reduced their sensitivity to treatment with this
HDACI. Conversely, reducing Ku70 levels in these cells
caused cell death even without HDACI treatment. This was
likewise dependent on Bax expression. Together with data
presented on the expression patterns of CBP, Ku70, and
Bax in a collection of human NB tumor specimens, our re-
sults showing that these proteins together mediate cell death
in response to TSA in NB cells provide evidence that these
proteins are potential biomarkers for predicting and moni-
toring treatment responsiveness to HDACIs in NB tumors.
Materials and Methods
Cell Culture and Cell Transfection
Human NB cell lines SH-SY5Y, IMR32, SH-EP1, SK-N-AS,
GOTO, SMS-KCN-69n, LA1-55n LA1-5s, SH-310, and WSN
were cultured in modified Eagle’s medium (MEM) sup-
plemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin. The cells were maintained
at 37jC in a humidified 5% CO2 incubator. For transient
transfection, SH-EP1 cells were transfected with the vector
pcDNA3-CBP-FLAG or pcDNA3-p300-FLAG, with or without
pCMV2B-Ku70 wild-type FLAG or pCMV2B-Ku70 K539/
542R-FLAG, and a green fluorescence protein (GFP) expres-
sion vector (Amaxa, Gaithersburg, MD) using Nucleofector
kit V (Amaxa). Briefly, immediately before transfection, 2 
106 cells were trypsinized, washed with phosphate-buffered
saline, and then resuspended in Nucleofector V solution
containing 5 mg of indicated plasmids along with 0.5 mg of
the GFP vector to a final concentration of 3  106 to 4 
106 cells/100 ml. Samples were subjected to nucleofection
using the Nucleofector device at settings recommended by
the manufacturer for SH-SY5Y cells (Amaxa). After transfec-
tion, cells were resuspended in prewarmed MEM and plated.
Twenty-four hours after transfection, the efficiency of trans-
fection was determined by GFP positivity.
Cell Viability Assays
Two S-type (SH-EP1 and SK-N-AS) and two N-type
(IMR32 and SH-SY5Y) human NB cell lines were treated with
different concentrations of TSA, and viability was determined
after 24 and 48 hours by MTTassay, as previously described
[4]. The viabilities of CBP-transfected and CBP knockdown
cells were similarly measured. All experiments were per-
formed at least three times, with triplicates in each experi-
ment. Data from a representative experiment are shown as
mean values and standard deviations.
siRNA-Mediated Silencing
Briefly, 24 hours before transfection, SH-SY5Y cells were
plated at a density of 2 106 cells per 10-cm plate. On the fol-
lowing day, cells were transfected with SMART-pool CBP
siRNA (Dharmacon, Inc., Lafayette, CO) using a Nucleofector
transfection reagent (Amaxa), as per the manufacturer’s pro-
tocol. As a measure of transfection efficiency, we used siGlo
(Dharmacon). Mock transfection and transfection with scram-
bled siRNA served as controls. siRNA-induced depletion of
CBP expression was measured 48 to 72 hours after transfec-
tion by Western blot analysis using CBP antibodies (06-893;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Western Blot Analysis and Coimmunoprecipitation
Whole-cell extracts of NB cell lines SH-SY5Y, IMR32, SH-
EP1, SK-N-AS, GOTO, SMS-KCN-69n, LA1-55n LA1-5s,
SH-310, and WSN were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to PDVF membrane, and then immunoblotted
for CBP, p300, Bax, or Ku70. Tubulin was used as a loading
control. The following antibodies were used for Western blot
analyses: tubulin (T-4026) and FLAG (F-1804) antibodies
were from Sigma (St. Louis, MO); Ku70 (A-9), CBP (A-22),
and p300 (N-15) antibodies were from Santa Cruz Bio-
chemicals; and Bax-NT (06-499) antibody was from Upstate
(Billerica, MA). Western blot analyses were visualized by using
Enhanced Chemiluminescence Plus (Amersham Pharmacia
Biotech, Piscataway, NJ). Coimmunoprecipitation of endoge-
nous and FLAG-tagged Ku70 before and after TSA treatment
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was performed in CHAPS buffer, according to the procedure
described by Sawada et al. [5].
NB Tissue Array
Tissue arrays were constructed using triplicate 1.0-mm
cores taken from 45 paraffin-embedded formalin-fixed
neuroblastic tumors (30 NBs, 7 ganglioneuroblastomas, 7
ganglioneuromas, and 5 composite/mixed-histology tumors),
5 normal adrenal glands, and 20 other neural crest–derived
and unrelated neoplasms. After constructing and curing
array cores in a paraffin block, 10-mm sections on poly-L-
lysine slides were taken for routine hematoxylin–eosin stain-
ing and immunohistochemistry. Staining was performed
according to the manufacturer’s recommended Immuno-
histochemistry (IHC) protocols using the same antibodies
described above. A semiquantitative system was used to
measure staining intensity, with a score from 0 to 3 assigned
to each component (neuroblastic and stromal) of each tumor
core. Mean scores and component ratios (neuroblast stain-
ing intensity divided by stromal cell staining intensity) were
then derived for each tumor from its triplicate cores. Corre-
lations between immunohistochemical staining and histo-
logic cell type were performed using bivariate analysis with
Pearson coefficients and two-tailed significance tests.
Results
S-Type NB Cells Are Less Sensitive to TSA and Have Lower
Levels of HATs Than N-Type Cells Growing in Culture
To determine the relative responsiveness of N-type and
S-type NB cell lines to TSA-induced cell death, we treated
two N-type (IMR32 and SH-SY5Y) and two S-type (SH-EP1
and SK-N-AS) NB cell lines with TSA for 24 or 48 hours, and
then measured cell viability with MTT assay. After 48 hours,
1 mM TSA reduced the viability of N-type cells to less than
10% to 20% (Figure 1A). In contrast, S-type cells were sig-
nificantly less sensitive to TSA: at 1 mM, viability remained
above 50% (Figure 1B). Consistent with our previous report,
TSA disrupts the molecular interaction between Ku70 and
Bax in N-type SH-SY5Y (Figure 2A, lanes 5 and 6) and
IMR32 cells (data not shown), which we proposed is due to
increased acetylation on Ku70 lysine residues K539 and
K542 [4]. In contrast, although SH-EP1 cells have similar
levels of Ku70–Bax complex detected in cytosolic extracts
(Figure 2A, lanes 1–4), TSA does not affect Bax and Ku70
binding in these cells (Figure 2A, lanes 7 and 8). These data
are generally consistent with findings recently reported by
Furchert et al. [12] comparing growth inhibition in response
to TSA and other HDACIs in a panel of cells, including five
Figure 1. TSA induces cell death in N-type, but not S-type, NB cells. N-type cell lines (IMR32 and SH-SY5Y) (A) and S-type cell lines (SH-EP1 and SK-N-AS) (B)
were treated with various concentrations of TSA for 24 or 48 hours, as indicated. Cell viability was determined by MTT assay. Results are expressed as the
percentage of viable cells compared with vehicle-treated controls (mean ± SD; n = 3).
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NB cell lines. With respect to sensitivity to HDACIs (TSA,
MS-275, and SAHA), they report that SHEP-SF cells, an
S-type line, are less responsive than N-type cells (CH-LA 90,
IMR-5, and SHSY-5Y), with a single exception in that SH-
SY5Y cells were relatively resistant to SAHA.
HDAC inhibition can only increase Ku70 acetylation when
HAT activity capable of acetylating the corresponding sensi-
tive sites is present. Hence, these results showing that TSA
fails to disrupt Ku70–Bax binding in S-type cells could be
explained by the possibility that the cells lack adequate HAT
expression or activity. To test this possibility, we determined
the relative expression of Ku70, Bax, p300, and CBP, the
last of which is known to acetylate Ku70 [10]. As shown
in Figure 2, B and C, the N-type (IMR32 and SH-SY5Y in
Figure 2B; GOTO, SMS-KCN-69n, and LA1-55n in Figure 2C)
and S-type (SH-EP1 and SK-N-AS in Figure 2B; LA1-5s,
SH-310, and WSN in Figure 2C) cell lines express nearly
equal amounts of Ku70 and Bax; however, the levels of CBP
and p300 are significantly lower in S-type cell lines than in
N-type cell lines.
Low-Level CBP Expression Limits the Responsiveness
of S-Type Cells to TSA Treatment
Next, we designed a series of experiments to determine
whether the level of expression of CBP or p300 governs
responsiveness to HDACIs in NB cell types. First, we tested
the hypothesis that increasing the level of CBP or p300 in
S-type cells would result in a more TSA-responsive pheno-
type. FLAG-tagged CBP or p300 expression vectors were
transiently transfected into SH-EP1 cells by an electropora-
tion method that results in a transfection efficiency of z 95%
(data not shown). Twenty-four hours after transfection,
SH-EP1 cell viability was assessed. Remarkably, although
the expression levels of FLAG-tagged CBP and p300 were
similar (Figure 3B), the transfection of CBP, but not p300,
had toxic effects; CBP reduced SH-EP1 viability to 30% of
vector-transfected control cells (Figure 3A). Mechanistically,
CBP transfection, but not p300 transfection, disrupted the
interaction between Bax and Ku70, as evidenced by the
failure to detect Bax in immune complexes precipitated with
anti-Ku70 antibody from CBP-transfected cells (Figure 3C).
Furthermore, when CBP or p300 transfection was combined
with TSA treatment, only CBP-transfected cells had increased
sensitivity to TSA-induced death (Figure 3D, left panel ).
These experiments were performed by harvesting cells that
remained viable after CBP transfection; these cells were then
treated with vehicle control, TSA, or doxorubicin (Dox). Unlike
the increased sensitivity to TSA seen in cells transfected with
CBP, there was no change in the sensitivity of cells to Dox,
which represents a cytotoxic agent that does not act by
blocking HDAC activity (Figure 3D, right panel ). Indeed, the
TSA dose response of CBP-transfected S-type cells was
comparable to that of N-type cells (Figure 1A). Together,
these results show that the level of expression of CBP in
S-type cell lines can independently affect Ku70–Bax binding
and that increased CBP expression enhances cell death in
response to TSA.
To directly link Ku70 acetylation with CBP-induced Bax
release, activation, and cell death, we took advantage of a
Ku70 mutant protein in which two acetylation-sensitive ly-
sine residues (539 and 542) were replaced by arginines. This
mutant has been previously shown to block TSA-induced
apoptosis in N-type cell lines [4]. As shown in Figure 4A, a
single cotransfection using the CBP and Ku70 plasmids
resulted in the expression of target proteins. It was noted
that the level of CBP expression was lower when Ku70
plasmid was also present, potentially due to transcription-
level interference. As expected, transfection to overexpress
wild-type Ku70 or Ku70 lysine mutant did not significantly
affect viability (84% and 95% of controls; Figure 4B, lanes 5
and 6, respectively), whereas CBP was toxic (52% viable;
Figure 4B, lane 2). Cotransfecting wild-type Ku70 along with
CBP resulted in slightly higher cell deaths (42% viability;
Figure 4B, lane 3) compared with transfecting CBP alone,
whereas cotransfection of Ku70 mutant completely blocked
the toxic effects of CBP overexpression (81% viability;
Figure 2. N-type NB cells have higher CBP and p300 levels, and Bax is released from Ku70 in response to TSA. (A) Both N-type (SH-SY5Y) and S-type (SH-EP1)
cells were treated with 1 M TSA or vehicle for 4 hours. Endogenous Ku70 was immunoprecipitated using goat anti-Ku70 antibodies or normal goat serum (NGS).
Immunoprecipitates were separated by SDS-PAGE and probed with anti-Bax or anti-Ku70 antibodies. Input represents 20% of the sample used in immuno-
precipitation. (B and C) Whole-cell extracts of N-type (IMR32 and SH-SY5Y in B; GOTO, SMS-KCN-69n, and LA1-55n in C) or S-type (SH-EP1 and SK-N-AS in B;
LA1-5s, SH-310, and WSN in C) NB cells were separated by SDS-PAGE and probed with anti-CBP, anti-p300, anti-Ku70, and anti-Bax antibodies. -Tubulin was
probed for equal loading.
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Figure 4B, lane 4). It is worth noting that the levels of CBP
expression were nearly equal in cotransfections with wild-
type Ku70 and with Ku70 mutant (Figure 4A); therefore,
differences in CBP expression do not account for differences
in cell survival. We monitored the Bax–Ku70 complex fol-
lowing each transfection. Consistent with effects on cell
survival, transfection of CBP alone or CBP with wild-type
Ku70 resulted in dissociation of Ku70–Bax (Figure 4C, lanes
6 and 7, respectively), whereas the complex remained intact
in cells cotransfected with CBP and Ku70mutant (Figure 4C,
lane 8). These results provide evidence that CBP depends
on critical acetylation-sensitive lysine residues in Ku70 for its
ability to disrupt the interaction between Ku70 and Bax in NB
cells. However, these interpretations may be limited by the
unphysiologically high level of CBP expression introduced by
transient transfection in these cells.
High-Level CBP Expression Is Required for HDACI-Induced
Cell Death in N-Type Cells
Our data suggest that CBP may be required to acetylate
Ku70 in NB cells. If so, we reasoned that depletion of CBP in
N-type cell lines should render cells less sensitive to TSA-
induced cell death. Using siRNA targeting CBP, we re-
duced CBP protein expression in SH-SY5Y cells (up to 90%;
Figure 5A). Depleting CBP in these cells significantly blocks
the cytotoxic response observed after 24 or 48 hours of TSA
treatment (Figure 5B). These results indicate that CBP is a
critical mediator of TSA-induced cell death.
Bax Is Required for TSA-Induced Cell Death in NB Cells
We used siRNA knockdown of Bax and Ku70 in SH-SY5Y
cells (Figure 6A) to determine whether Bax is required for
TSA-induced killing and to establish whether the balance in
the expression of Ku70 and Bax can affect viability. Consis-
tent with the model developed above, reducing Bax expres-
sion in SH-SY5Y cells protects cells from TSA-induced death
(Figure 6C). Knocking down Bax expression, by itself, does
not affect NB cell viability, whereas Ku70 knockdown alone
led to cell death, even without TSA treatment (Figure 6B).
SH-SY5Y cells survived Ku70 knockdown, however, when
Bax was simultaneously knocked down and, as expected,
death response to TSA was significantly reduced in double-
knockdown cells (Figure 6C). These results show both that
the Ku70–Bax complex is a relevant target for therapeutic
Figure 3. Increasing CBP in S-type NB cells reduces cell viability and Bax binding to Ku70. SH-EP1 (S-type) cells were transfected with FLAG-tagged CBP, FLAG-
tagged p300 expression vector, or empty vector. (A) Cell viability was determined by MTT assay 24 hours after transfection. Results are expressed as the percentage
of viable cells compared with vehicle-treated controls (mean ± SD; n = 3). (B) The levels of CBP and p300 after transfection, as described above, are detected by
immunoblotting with anti-FLAG, anti-CBP, and anti-p300 antibodies, as shown. -Tubulin was probed for equal loading. (C) SH-EP1 cells were transfected with FLAG-
tagged CBP, FLAG-tagged p300 expression vectors, or empty vector. Twenty-four hours after transfection, Ku70 was immunoprecipitated using goat anti-Ku70
antibodies or NGS. Immunoprecipitates were separated by SDS-PAGE and probed with anti-Ku70 or anti-Bax antibodies. Input represents 20% of the sample used
for immunoprecipitation. (D) SH-EP1 cells were transfected with FLAG-tagged CBP, FLAG-tagged p300 expression vector, or empty vector. Twenty-four hours
after transfection, cells remaining viable were treated with various concentrations of TSA or Dox, as indicated, for an additional 24 hours, after which viability was
determined by MTT assay. Results are expressed as the percentage of viable cells compared with vehicle-treated controls (mean ± SD; n = 3).
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Figure 4. Coexpression of a Ku70 acetylation mutant rescues CBP-induced reduction of cell viability in S-type NB cells. SH-EP1 (S-type) cells were transfected
with FLAG-tagged CBP, FLAG-tagged wild-type Ku70, or FLAG-tagged Ku70 mutant (K539R/K542R) expression vectors, as indicated. The expression of
transfected proteins is shown in (A) by immunoblotting using anti-FLAG antibodies. -Tubulin was probed for equal loading. (B) Twenty-four hours after TSA
treatment, cell viability was determined by MTT assay. Results are expressed as the percentage of viable cells compared with vector alone (mean ± SD; n = 3). (C)
Twenty-four hours after transfection, Ku70 was immunoprecipitated using goat anti-Ku70 antibodies or NGS. Immunoprecipitates were separated by SDS-PAGE
and probed with anti-Ku70 or anti-Bax antibodies. Input represents 20% of the sample used in immunoprecipitation.
Figure 5. Reduction of CBP in N-type NB cells reduces TSA-induced cell death. (A) SH-SY5Y (N-type NB) cells were transfected with CBP-specific siRNA (5 or
10 nM) or scrambled siRNA. The control received no siRNA. Forty-eight hours after transfection, the level of CBP was determined by immunoblotting using anti-
CBP antibodies. -Tubulin was probed for equal loading. (B) Forty-eight hours after siRNA transfection, the cells were treated with various concentrations of TSA
for 24 or 48 hours, as indicated. Cell viability was then determined by MTT assay. Results are expressed as the percentage of viable cells compared with vector
alone (mean ± SD; n = 3).
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strategies to decrease NB survival and that Bax expression
is required for TSA-induced cell death.
Proteins Required for HDACI-Induced Cell Death Are
Expressed in Human NB Tumors
Next, we determined the protein-level expression of Bax,
Ku70, and CBP in human NB tumors to assess the potential
of these proteins to be developed as biomarkers to select
tumors that are most likely to respond to HDACIs. To do
this, we constructed NB tumor tissue microarrays and used
immunohistochemical detection methods to semiquantita-
tively determine the expression of Bax, Ku70, CBP, and
p300 (Figure 7A).
We found that every NB tumor had detectable levels of
these proteins. This suggests that the critical components of
the TSA response mechanism defined in vitro are present
in tumors. It is interesting to note that CBP and p300 are
expressed at higher levels in neuroblastic regions of tumors
compared to the stroma (the CBP neuroblast/stroma ratio is
3.65), although there is a smaller difference in the expression
of Ku70 or Bax between neuroblastic and stromal regions
(neuroblastic/stromal ratios are 2.21 and 1.36, respectively).
Semiquantitative analyses of CBP and p300 expression
levels in neuroblastic foci reveal that > 90% of tumors dem-
onstrate expression that reaches the upper half of the range
(levels 2 and 3) (Figure 7B). In contrast, CBP and p300
expression in stromal regions reaches the upper range in
only 20% to 35% of tumors and is barely detectable in > 35%
of stromal regions. Thus, CBP and p300 are differentially
expressed between neuroblastic and stromal cell regions in
tumors, mirroring the differential expression observed be-
tween N-type and S-type NB cell lines. In addition to dem-
onstrating the presence of these proteins in all NB tumor
specimens, these data show a range for the expression for
each protein across tumors that varies according to neuro-
blastic and stromal histology. The differences in expression
observed across this small set of NB tumors support the pos-
sibility of detecting correlations between the expression of
Figure 6. Ku70 and Bax are critical for TSA-induced death of N-type NB cells. (A) SH-SY5Y cells were transfected with scrambled, Bax (10 nM), Ku70 (10 nM), or
both Bax/Ku70– targeted siRNA. The levels of Bax or Ku70 protein at 48 hours after transfection are shown in immunoblots using Bax-specific or Ku70-specific
antibodies. -Tubulin was probed for equal loading. (B) Forty-eight hours after siRNA transfection, the viability of Bax, Ku70, or Ku70/Bax knockdown in SH-SY5Y
cells was determined by trypan blue exclusion assay. The results are expressed as percentages of viable cells relative to cells transfected with scrambled siRNA
(mean ± SD; n = 3). (C) Forty-eight hours after siRNA transfection, Bax or Ku70/Bax knockdown in SH-SY5Y cells was treated with various concentrations of TSA,
as shown. The viability of cells was determined by MTT assay 24 or 48 hours after TSA treatment by comparison to untreated SH-SY5Y cells. The results are
expressed as mean ± SD (n = 3).
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levels of CBP, Ku70, or Bax and clinical variables such as
responses to HDACI treatment in a future translational study.
Discussion
Our results support a model in which the association of Bax
with Ku70 in NB cells defines a target for TSA and in which
response to TSA treatment is regulated by CBP. This model
further predicts that the sensitivity of NB tumor cells to the
apoptotic effects of certain HDACIs depends on the three
components: Ku70, Bax, and CBP. We have tested this
model in S-type NB cell lines in which the level of CBP is
low. Overexpression of CBP in S-type cell lines favors the
dissociation of Bax from Ku70, increasing the sensitivity of
these cells to TSA. A Ku70 acetylation site mutant, which we
have previously shown, blocks the apoptotic effects of HDA-
CIs in N-type NB cell lines and also blocks CBP-induced cell
death in S-type NB cells. Conversely, reducing CBP expres-
sion in N-type NB cell lines significantly reduces the cytotoxic
effects of TSA, further establishing that CBP is a factor
determining HDACI responsiveness. The results of experi-
ments in which Bax and Ku70 expression was modulated
not only support the importance of the interaction between
Bax and Ku70 in maintaining NB cell viability but also dem-
onstrate that TSA-induced cell death in NB cells depends on
these proteins because cells lacking both Ku70 and Bax are
insensitive to HDACI-induced killing.
CBP Mediates Cell Death By Affecting Ku70–Bax Binding
in the Cytoplasm
Our results suggest that CBP acetylates Ku70 as part of a
mechanism leading to the disruption of cytoplasmic Ku70–
Bax complexes. These data are consistent with a model in
which CBP, typically considered a nuclear protein, may be
active in the cytoplasm where it acetylates Ku70. CBP and
the related molecule p300 have previously been detected in
the cytoplasm of other cells. For example, CPB and p300 are
cytoplasmic in mouse oocytes isolated from primordial fol-
licles, but as follicles develop, oocyte CBP and p300 become
progressively localized in the nucleus [13]. Cohen et al. [10]
have shown that, after HDACI treatment, CBP translocates
from the nucleus to the cytoplasm in 293Tcells. In NB, HeLa,
and HEK 293 cells, we have recently demonstrated that CBP
and p300 are detected in both the cytoplasm and the nucleus
(manuscript in preparation). These results provide for the
possibility that cytoplasmic CBP acetylates Ku70. It is also
possible that the interaction between CBP and Ku70 occurs
in the nucleus and that shuttling of Ku70 between the nu-
cleus and the cytoplasm allows the acetylation that occurs in
the nucleus to ultimately affect the binding equilibrium of
cytoplasmic Ku70 and Bax. Ongoing work is directed at
answering this question.
CBP, But Not p300, Reduces the Viability of S-Type
NB Cells
Because CBP and p300 are highly homologous (61%
identical at the amino acid level overall, and 95% similar in
functional domains), it is surprising that only the expression of
CBP, and not p300, is cytotoxic to S-type NB cells (Figure 3).
CBP and p300 are functionally equivalent in terms of their
interactions with many cellular proto-oncogenes and a wide
variety of transcription factors [14]. Mutations of CBP and
p300 in humans are both associated with the Rubinstein-Taybi
syndrome, a developmental disorder characterized by mental
retardation, digital abnormalities, and an increased incidence
of certain types of tumors, including NB [15,16]. Nevertheless,
Figure 7. Expression of Bax, Ku70, and CBP in a tissue microarray of neuroblastic tumors. (A) Cores of formalin-fixed paraffin-embedded neuroblastic tumors
were stained using peroxidase-conjugated anti-Bax, anti-Ku70, or anti-CBP antibodies (brown signals). The slides were then counterstained with hematoxylin (blue
background). (B) Fraction of N-type or S-type cells that express different staining intensities (levels, 0–3+) of CBP, p300, Ku70, or Bax in our NB tissue micro-
array studies.
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several examples provide evidence that the functions of CBP
and p300 do not completely overlap. In F9 cells, retinoic acid–
induced differentiation is dependent on p300, but not CBP,
because expressing a p300-specific hammerhead ribozyme
capable of cleaving p300 messenger RNA, but not CBP,
makes these cells resistant to retinoic acid–induced differen-
tiation [17]. Although p300, and not CBP, is crucial for proper
hematopoietic differentiation [18], only CBP is essential for
hematopoietic stem cell self-renewal. The results in the cur-
rent study show that CBP and p300 are not functionally
equivalent in NB cells and suggest that this may result from
differences in substrate specificity for Ku70 acetylation. The
precise mechanism that determines CBP and p300 substrate
specificity remains an area of intense research interest.
Clinical Relevance
NB tumors are comprised of neuroblastic and stromal
cells [19,20]. Differences in the proportion of neuroblastic
and schwannian stromal cells present in neuroblastic tu-
mors, which include NB, ganglioneuroblastoma, and ganglio-
neuroma, are one of the important criteria used to establish
clinical prognosis. Tumors that are composed primarily of
neuroblasts and have low numbers of schwannian stromal
cells are more aggressive and are usually the most difficult
to cure [21,22]. Our analysis of a panel of neuroblastic tu-
mors identifies a difference in the level of CBP expression
between neuroblastic and schwannian stromal cells. Spe-
cifically, neuroblastic cells express three-fold more of this
protein. Because TSA is more active against N-type cells
compared to S-type cells in culture and because its killing
depends on adequate CBP expression, we predict that
HDACIs will preferentially kill neuroblastic cells within these
tumors, which may mean that tumors with higher neuro-
blastic content (NBs) will respond better to these agents than
stromal-predominant ones (ganglioneuromas). Further ex-
periments and clinical trials that validate the safety and ef-
ficacy of HDACIs in patients with neuroblastic tumors may
consider evaluating whether clinical variables, including
responses to this therapeutic class, correlate with the ex-
pression of Bax, Ku70, and CBP.
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